Expansion of Capital Allocation Plan
Summary by AI BETAClose X
LEI: 549300Q7EXQQH6KF7Z84
9 November 2026
RTW Biotech Opportunities Ltd
Expansion of Capital Allocation Plan
● $42.3 million of total $45 million commitment returned to shareholders via share buybacks
● Up to 20% of realised gains from M&A transactions to be allocated to liquidity pool for capital returns
● Further $42.8 million to be allocated to liquidity pool available for share buybacks (4.9% of NAV)
RTW Biotech Opportunities Ltd (the “Company”), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to announce an expansion to its Capital Allocation Plan.
Chair of the Company, William Simpson, commented:
“Now having returned almost the entire $45 million targeted to be returned to shareholders since the sale of Prometheus, the Board is pleased to formalise a policy of allocating up to 20% of realised gains from M&A transactions to a liquidity pool that can be used to return capital to shareholders. Today, a further $42.8 million is being committed to this liquidity pool, earmarked for NAV-accretive share buybacks. The Board maintains a disciplined approach to capital allocation, balancing growth and reinvestment into the portfolio at a generational moment for biotech with direct returns from successful exits.”
Background
The Company continuously evaluates share buybacks through a broader capital allocation lens, anchored and focused on the core objective of long-term capital growth while recognising that maintaining sufficient liquidity is critical to protect and grow value in our portfolio companies over time. The Company also wishes for shareholders to participate in the liquidity generated from successful investment exits. The Company has previously stated that, should a significant cash inflow (e.g. through a portfolio position being acquired) be received, it remains the Board's intention to consider the return of a portion of the realised gain to shareholders through NAV-accretive share buybacks.
Pursuant to the Company’s announcement of 20 October 2025, the Company committed to return $45 million of realised gains to deliver on this objective, which is now almost complete. As at 5 November 2026, $42.3 million has been returned to shareholders via share buybacks. In the year to 5 November 2026, the Company has repurchased 7.2 million shares.
Recent M&A activity
Biotech M&A rebounded sharply in 2025 with $126 billion of deals done, more than double the total for 2024. This acceleration in activity has continued into 2026 where $120 billion of transactions have been announced for the year to 30 September 2026. The Company expects 2026 to be one of the best years on record for biotech M&A deal volumes.
Following the Capital Allocation Plan announcement on 20 October 2025, the Company is pleased to provide an update on M&A activity within the portfolio since:
● On 26 October 2025, Novartis announced the $12 billion acquisition of Avidity (7.0% of NAV) at a 46% premium to Avidity’s last closing price.
● On 15 January 2026, Boston Scientific announced the $14.5 billion acquisition of Penumbra (1.0% of NAV) at a 19% premium to Penumbra’s last closing price.
● On 20 January 2026, GSK announced the $2.2 billion acquisition of RAPT Therapeutics (0.2% of NAV) at a 65% premium to RAPT’s last closing price.
● On 31 March 2026, Eli Lilly announced the $6.3 billion acquisition of Centessa (0.2% of NAV) at a 38% premium to Centessa’s last closing price, and Biogen announced the $5.6 billion acquisition of Apellis (1.1% of NAV) at a 140% premium to Apellis’ last closing price.
● On 22 June 2026, AbbVie announced the $10.9 billion acquisition of Apogee (1.1% of NAV) at a 49% premium to Apogee’s last closing price.
● On 18 August 2026, BioMarin announced the acquisition of private investment Alesta (0.4% of NAV) for $275 million upfront, representing an estimated 41% uplift on the Company’s carrying value.
Most of the transactions detailed above have been take-privates of public investments and primary market activity in biotech continues apace. In 2026, the Company’s private investments have announced or completed four reverse mergers, three IPOs, and one SPAC merger (Corxel, the Company’s largest private holding).
Updated Capital Allocation Plan
The Board recognises that a more formulaic Capital Allocation Plan would provide shareholders with greater clarity on returns. To that end, the Company is today enhancing its approach. Should the Company receive a significant cash inflow (e.g. through a portfolio position being acquired), the Board may allocate up to 20% of the realised gain to a liquidity pool that can be used to return capital to shareholders e.g. through NAV-accretive share buybacks.
Furthermore, given that the Company has returned almost the entirety of the $45 million initially targeted and in light of a number of recent successful M&A transactions by portfolio companies as set out above, the Board announces that it intends to allocate a further $42.8 million (equivalent to 4.9% of NAV as at 30 September 2026) to a liquidity pool available for NAV-accretive share buybacks, to be implemented over time at its discretion. This $42.8 million allocation represents 20% of the uplifts from M&A transactions since and including Prometheus (net of such uplifts returned via share buybacks to 5 November 2026) and is additional to the aggregate $45 million previously announced, of which a residual $2.7 million remains outstanding. Therefore, as at 5 November 2026, the liquidity pool comprises $45.5 million (5.3% of NAV as at 30 September 2026).
Enquiries:
|
RTW Investments, LP – Investment Manager Oliver Kenyon Krisha McCune (Investor Relations)
|
+44 (0)20 7959 6362 biotechopportunities@rtwfunds.com |
|
Cadarn Capital – PR & IR Partner Lucy Clark (PR) David Harris (Distribution) |
+44 (0)7984 184 461 +44 (0)7368 883 211
|
|
Jefferies International Limited – Joint Corporate Broker Gaudi Le Roux Harry Randall-Knowles
|
+44 (0)20 7029 8000 |
|
BofA Securities – Joint Corporate Broker Edward Peel Alex Penney
|
+44 (0)20 7628 1000 |
|
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison
|
+44 (0)1481 703 100 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwbio.com for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity’s business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.
The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 hours ago ASOS
- 5 hours ago MJ Gleeson
- 5 hours ago Rolls-Royce Holdings
- 6 hours ago Crest Nicholson Holdings
- 6 hours ago Naked Wines